 MILAN, Italy and NEW YORK, Feb. 24, 2022 GLOBE NEWSWIRE -- Genenta Science NASDAQ: GNTA, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer TemferonTM, announced today that management will be participating in the following upcoming investor conferences: 